Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0644120090220010263
Journal of Oriental Gynecology
2009 Volume.22 No. 1 p.263 ~ p.278
Recent Studies of Breast Cancer in Traditional Chinese Medicine Journals
Jeong Ui-Min

Jeong Jong-Soo
Park Jae-Woo
Jung Hyun-Sik
Yoon Seong-Woo
Abstract
Purpose: The purpose of this study is to research trends in the study of breast cancer in Traditional Chinese Medicine (TCM) and to establish the further direction for its study.

Methods: We reviewed TCM papers published in the last 29 years (1979-2008).

Results: 1. We researched 49 papers and the patterns of study were as follows: in vitro studies were 27 papers (55.1%), in vivo studies were 9 papers (18.4%) and clinical studies were 19 papers (38.8%). 2. In vitro studies on breast cancer research in TCM were focused on cytotoxicity (17 papers) and apoptosis (8 papers). Most of in vivo studies (6 papers) were done for the purpose of inducing growth suppression of tumor cell after administration of the test drug. Each drug acted on this effect through various types of mechanism. 3. Unlike in vitro and in vivo studies, clinical studies on growth suppression of tumor cell were rare (4 papers). Most of the studies were focused on reduction of side effect of chemotherapy or synergistic effect with chemotherapy (7 papers), immune regulation (7 papers), and improvement of quality of life (6 papers). 4. Among the treatment method we reviewed, ¡¯Runing ¥±(¥±ûÜÛ°)¡¯ was the only medication that further studied as clinical trial after experimental study. 5. Since almost all studies have defects like poorly designed model or insufficient data description, it was difficult to make any definite conclusion about these studies. Conclusion: More subsequent clinical studies based on experimental study will be needed afterwards. Strict and high-level study design with detailed description will be needed in further study.
KEYWORD
Breast cancer, Traditional chinese medicine (TCM)
FullTexts / Linksout information
 
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI)